5-Fluorouracil: mechanisms of action and clinical strategies
The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Abstract
5-fluorouracil (5-FU) is widely used in the treatment of cancer. Over the past 20 years, increased understanding of the mechanism of action of 5-FU has led to the development of strategies that increase its anticancer activity. Despite these advances, drug resistance remains a significant limitation to the clinical use of 5-FU. Emerging technologies, such as DNA microarray profiling, have the potential to identify novel genes that are involved in mediating resistance to 5-FU. Such target genes might prove to be therapeutically valuable as new targets for chemotherapy, or as predictive biomarkers of response to 5-FU-based chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“5-FU exerts its anti-cancer effects by inhibiting thymidylate synthase (TS) and incorporating its metabolites into RNA and DNA [4].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“5-FU mainly destroys the deoxynucleotide pool required for DNA replication by inhibiting thymidylate synthase (TS), and mixes its metabolites into RNA and DNA to exert anti-tumor effects [4,127].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“Several studies have shown that the high expression of TS is a crucial determinant of CRC resistance to 5-FU”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“and 5-FU intervention can also increase the expression of TS [4,9,10].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“MutSα recognizes and associates with FdU:G mismatch pairs in an in vitro binding experiment”
From Functional interplay between ATM/ATR-mediated DNA damage response and DNA repair pathways in oxidative stress (2014) · cites this paper as [210]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.
Miyashita, T., Krajewski, S., Krajewska, M., Wang, H., Lin, H., Liebermann, D. A., Hoffman‐Liebermann, B., & Reed, J. C. (1994) · PubMed · Cited by 2,143
A gene expression database for the molecular pharmacology of cancer
Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259 · cited 1×
“Irinotecan is a topoisomerase I inhibitor and is active in the first- and second-line treatment of advanced colorectal cancer, in which it has shown improved survival and quality of life when compared with best supportive care in patients who have failed 5-FU/L”
Miwa, M., Ura, M., Nishida, M., Sawada, N., Ishikawa, T., Mori, K., Shimma, N., Umeda, I., & Ishitsuka, H. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00058-6 · Cited by 1,240
(1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.6.896 · Cited by 1,189
Hoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2282 · Cited by 1,130
Research works printed but not linked: 2
- Rutman, R. J., Cantarow, A. & Paschkis, K. E. Studies on 2-acetylaminofluorene carcinogenesis: III. The utilization of uracil-2-C14 by pre–neoplastic rat liver. Cancer Res. 14, 119 (1954).
- Jackson, R. C. & Grindley, G. B. The Biochemical Basis for Methotrexate Cytotoxicity (eds Sirotnak, F. M., Burchall, J. J., Ensminger, W. D. & Montgomery, J. A.) 289–315 (Academic, New York, 1984).
Cited by
Items 201–300 of 1,028
Khan, A. Q., Rashid, K., AlAmodi, A. A., Agha, M. V., Akhtar, S., Hakeem, I., Raza, S. S., & Shahab Uddin, M. S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112142 · Cited by 174
Shakibaei, M., Kraehe, P., Popper, B., Shayan, P., Goel, A., & Buhrmann, C. (2015) · BMC Cancer · doi:10.1186/s12885-015-1291-0 · Cited by 158
“5-FU treatment blocks cancer cell proliferation and induces apoptosis by incorporation of its metabolites into DNA and RNA as a thymidylate synthase inhibitor to block dTMP synthesis [37].”
Van Woensel, M., Wauthoz, N., Rosière, R., Amighi, K., Mathieu, V., Lefranc, F., Van Gool, S., & De Vleeschouwer, S. (2013) · Cancers · doi:10.3390/cancers5031020 · Cited by 158
“It is a pyrimidine analog, and will irreversibly inhibit the thymidylate synthase enzyme [65].”
BackgroundFTIR and circular dichroism spectroscopic study of interaction of 5-fluorouracil with DNA
Jangir, D. K., Charak, S., Mehrotra, R., & Kundu, S. (2011) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/j.jphotobiol.2011.08.003 · Cited by 160
[Ru(bpy)2(5-cyanouracil)2]2+ as a Potential Light-Activated Dual-Action Therapeutic Agent
Garner, R. N., Gallucci, J. C., Dunbar, K. R., & Turro, C. (2011) · Inorganic Chemistry · doi:10.1021/ic201615u · Cited by 158
Anitha, A., Sreeranganathan, M., Chennazhi, K. P., Lakshmanan, V., & Jayakumar, R. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.04.017 · Cited by 163
Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity
Realini, N., Solorzano, C., Pagliuca, C., Pizzirani, D., Armirotti, A., Luciani, R., Costi, M. P., Bandiera, T., & Piomelli, D. (2013) · Scientific Reports · doi:10.1038/srep01035 · Cited by 166
Activation of the tumor suppressor p53 upon impairment of ribosome biogenesis
Bursać, S., Brdovčak, M. C., Donati, G., & Volarević, S. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.08.014 · Cited by 180
La, X., Zhang, L., Li, Z., Li, H., & Yang, Y. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.8b06665 · Cited by 154
Guo, J., Yu, Z., Sun, D., Zou, Y., Liu, Y., & Huang, L. (2021) · Molecular Cancer · doi:10.1186/s12943-020-01297-0 · Cited by 158
MicroRNAs as therapeutic targets in chemoresistance
Garofalo, M., & Croce, C. M. (2013) · Drug Resistance Updates · doi:10.1016/j.drup.2013.05.001 · Cited by 153
“An example is fluorouracil resistance due o increased level of thymidylate synthase (Longley et al., 2003).”
BackgroundNitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility
Williams, E. M., Little, R. F., Mowday, A. M., Rich, M. H., Chan-Hyams, J. V. E., Copp, J. N., Smaill, J. B., Patterson, A. V., & Ackerley, D. F. (2015) · Biochemical Journal · doi:10.1042/bj20150650 · Cited by 171
In‐Cell Dual Drug Synthesis by Cancer‐Targeting Palladium Catalysts
Clavadetscher, J., Indrigo, E., Chankeshwara, S. V., Lilienkampf, A., & Bradley, M. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201702404 · Cited by 156
Polymer Implants for Intratumoral Drug Delivery and Cancer Therapy
Weinberg, B. D., Blanco, E., & Gao, J. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21038 · Cited by 159
“Some drug molecules, such as 5-fluorouracil, bind irreversibly to their therapeutic target, after which they are no longer in the population of available drug.(72) More generally, cells have a variety of nonspecific methods for detoxification, such as organelles for breaking down foreign molecules through enzymatic or…”
BackgroundChang, C.-T., Ho, T.-Y., Lin, H., Liang, J.-A., Huang, H.-C., Li, C.-C., Lo, H.-Y., Wu, S.-L., Huang, Y.-F., & Hsiang, C.-Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031808 · Cited by 153
“It kills tumor cells through interfering DNA synthesis and affecting protein synthesis [2].”
Etienne-Grimaldi, M.-C., Formento, J.-L., Francoual, M., François, E., Formento, P., Renée, N., Laurent-Puig, P., Chazal, M., Benchimol, D., Delpero, J.-R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4906 · Cited by 151
Davalli, P., Marverti, G., Lauriola, A., & D’Arca, D. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/2389523 · Cited by 164
“Pemetrexed (PMX) and 5-FU are folate cycle inhibitors that also promote cytochrome c release frommitochondria and interfere with the electron transport chain, resulting in O2⨪ radical production and cell death [161, 162].”
BackgroundResistance mechanisms to cancer chemotherapy
Redmond, K. M. (2008) · Frontiers in Bioscience · doi:10.2741/3070 · Cited by 150
“Resistance to chemotherapy can be caused by alterations in the drug target, for example, the 5-FU target enzyme TS is acutely up-regulated by 5-FU treatment (19).”
BackgroundInfluentialDNA Methylation and Cancer Development: Molecular Mechanism
Akhavan‐Niaki, H., & Samadani, A. A. (2013) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-013-9555-2 · Cited by 158
Kang, K. A., Piao, M. J., Kim, K. C., Kang, H. K., Chang, W. Y., Park, I. C., Keum, Y. S., Surh, Y. J., & Hyun, J. W. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.149 · Cited by 149
“The fluoropyrimidine 5-fluorouracil (5-FU) is an anticancer drug that is widely used in the treatment of solid tumors, including colorectal cancers (CRCs).(1) The mechanism of 5-FU action has been associated with the inhibition of thymidylate synthase and the incorporation of 5-FU into RNA and DNA.”
BackgroundInfluentialMokarram, P., Albokashy, M., Zarghooni, M., Moosavi, M. A., Sepehri, Z., Chen, Q. M., Hudecki, A., Sargazi, A., Alizadeh, J., Moghadam, A. R., et al. (2017) · Autophagy · doi:10.1080/15548627.2017.1290751 · Cited by 159
B24N24 fullerene as a carrier for 5-fluorouracil anti-cancer drug delivery: DFT studies
Hazrati, M. K., Javanshir, Z., & Bagheri, Z. (2017) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2017.08.003 · Cited by 149
“Despite the wide usage of 5-fluorouracil (5FU) in chemotherapy, its resistance and low bioavailability remain a major limitation to the clinical application [1].”
BackgroundBuhrmann, C., Shayan, P., Kraehe, P., Popper, B., Goel, A., & Shakibaei, M. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.08.105 · Cited by 153
“This process inhibits cell proliferation by suppressing DNA production [74].”
Wigmore, P. M., Mustafa, S., ELBeltagy, M., Lyons, L., Umka, J., & Bennett, G. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-6306-2_20 · Cited by 156
McEwan, C., Kamila, S., Owen, J., Nesbitt, H., Callan, B., Borden, M. A., Nomikou, N., Hamoudi, R., Taylor, M., Stride, E., et al. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.11.033 · Cited by 148
“We hypothesise that as antimetabolite therapy and SDT exert their cytotoxic effects via different mechanisms (the former through thymidylate synthase inhibition [12] and the latter through oxidation of cellular substrates [13]) their combination in a single therapeutic regime may provide significant patient benefit.”
El‐Hammadi, M. M., Delgado, Á. V., Melguizo, C., Prados, J. C., & Arias, J. L. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.11.012 · Cited by 148
Redox Paradox: A Novel Approach to Therapeutics-Resistant Cancer
Chaiswing, L., St. Clair, W. H., & St. Clair, D. K. (2018) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7485 · Cited by 145
“5-FU generates mitochondrial ROS via a p53-dependent pathway (205).”
BackgroundBrezovšek, P., Eleršek, T., & Filipič, M. (2014) · Water Research · doi:10.1016/j.watres.2014.01.007 · Cited by 162
The σ2 Receptor: A Novel Protein for the Imaging and Treatment of Cancer
Mach, R. H., Zeng, C., & Hawkins, W. G. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301545c · Cited by 142
Cancer chemoresistance; biochemical and molecular aspects: a brief overview
Kachalaki, S., Ebrahimi, M., Khosroshahi, L. M., Mohammadinejad, S., & Baradaran, B. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.03.025 · Cited by 161
Zhao, M., Tao, F., Venkatraman, A., Li, Z., Smith, S. E., Unruh, J., Chen, S., Ward, C., Qian, P., Perry, J. M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.093 · Cited by 146
“Paradoxically, despite their quiescence, the majority of HSCs cannot survive chemotherapeutic stress such as 5FU (Longley et al., 2003).”
BackgroundMutations and polymorphisms in TP53 gene--an overview on the role in colorectal cancer
Naccarati, A., Polakova, V., Pardini, B., Vodickova, L., Hemminki, K., Kumar, R., & Vodicka, P. (2012) · Mutagenesis · doi:10.1093/mutage/ger067 · Cited by 143
Pyridine and Pyrimidine Derivatives as Privileged Scaffolds in Biologically Active Agents
Chiacchio, M. A., Iannazzo, D., Romeo, R., Giofrè, S. V., & Legnani, L. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180904125400 · Cited by 145
Zhang, J., Simpson, C. M., Berner, J., Chong, H. B., Fang, J., Ordulu, Z., Weiss‐Sadan, T., Possemato, A. P., Harry, S. A., Takahashi, M., et al. (2023) · Cell · doi:10.1016/j.cell.2023.04.026 · Cited by 155
Soares, P. M. G., Mota, J. M., Gomes, A. S., de Oliveira, R. B., Assreuy, A. M. S., Brito, G. A. D. C., dos Santos, A. A., Ribeiro, R. A., & de Souza, M. H. L. P. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0715-9 · Cited by 144
Stuttmann, J., Barthel, K., Martin, P., Ordon, J., Erickson, J. L., Herr, R., Ferik, F., Kretschmer, C., Berner, T., Keilwagen, J., et al. (2021) · The Plant Journal · doi:10.1111/tpj.15197 · Cited by 159
MDMX regulation of p53 response to ribosomal stress
Gilkes, D. M., Chen, L., & Chen, J. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601424 · Cited by 142
“To confirm that 5-FU activates p53 by inhibiting RNA metabolism, HCT116 cells were treated with 5-FU in the presence of uridine, which bypassed inhibition of uridine synthesis by 5-FU (Longley et al, 2003).”
BackgroundIdentification of genes conferring resistance to 5-fluorouracil
Yoo, B. K., Gredler, R., Vozhilla, N., Su, Z.-Z., Chen, D., Forcier, T., Shah, K., Saxena, U. H., Hansen, U. M., Fisher, P. B., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901451106 · Cited by 151
“5-FU is converted into its inactive metabolite fluoro-5,6-dihydrouracil (FUH2) by dihydropyrimidine dehydrogenase (DPYD) (37).”
BackgroundZhou, C., & Fang, J. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.05.001 · Cited by 159
Kumar, G. V., Nair, L., Sankar, J., & Nair, S. A. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s20165 · Cited by 142
“Since 5-FU interferes with DNA synthesis, it principally acts as a thymidylate synthase inhibitor.(8,9) However, short half-life, wide distribution, and various side effects limit its medical applicability.”
Impact of 5 fluorouracil chemotherapy on gut inflammation, functional parameters, and gut microbiota
Sougiannis, A. T., VanderVeen, B. N., Enos, R. T., Velázquez, K. T., Bader, J. E., Carson, M. S., Chatzistamou, I., Walla, M. D., Pena, M. M., Kubinak, J. L., et al. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.02.020 · Cited by 152
Dendrimers in anticancer drug delivery: mechanism of interaction of drug and dendrimers
Singh, J., Jain, K., Mehra, N. K., & Jain, N. K. (2016) · Artificial Cells Nanomedicine and Biotechnology · doi:10.3109/21691401.2015.1129625 · Cited by 144
Redox-Mediated Mechanism of Chemoresistance in Cancer Cells
Kim, E.-K., Jang, M., Song, M.-J., Kim, D., Kim, Y., & Jang, H. H. (2019) · Antioxidants · doi:10.3390/antiox8100471 · Cited by 141
Lunenburg, C. A. T. C., Henricks, L. M., Guchelaar, H., Swen, J. J., Deenen, M. J., Schellens, J. H. M., & Gelderblom, H. A. J. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.008 · Cited by 139
Li, P., Zhang, X., Wang, L., Du, L., Yang, Y., Liu, T., Li, C., & Wang, C. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2017.07.007 · Cited by 140
“It is reported that a large proportion of an injected doseof 5FU is degraded by the extracellular enzyme dihydropyrimidine dehydrogenase, inducing 5FU resistance.(44) Moreover, 5FU is a prodrug that requires several intracellular enzymatic steps before it is converted to its other active metabolites, such as fluorodeo…”
BackgroundVatanparast, M., & Shariatinia, Z. (2018) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2018.04.003 · Cited by 139
Safwat, M. A., Soliman, G. M., Sayed, D. M., & Attia, M. A. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00047 · Cited by 151
Combatting the evolution of antifungal resistance in Cryptococcus neoformans
Bermas, A., & Geddes‐McAlister, J. (2020) · Molecular Microbiology · doi:10.1111/mmi.14565 · Cited by 155
Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications
Song, H., Liu, D., Dong, S., Zeng, L., Wu, Z., Zhao, P., Zhang, L., Chen, Z.-S., & Zou, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00300-w · Cited by 137
Crea, F., Nobili, S., Paolicchi, E., Perrone, G., Napoli, C., Landini, I., Danesi, R., & Mini, E. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.08.001 · Cited by 137
“5-Fluorouracil 5-FU was developed more than 50 years ago (Heidelberger et al., 957) and continues to be the backbone of treatment for patients ith early or advanced colorectal cancer (Longley et al., 2003; NCCN uidelinesTM Colon Cancer, 2011).”
BackgroundTsesmetzis, N., Paulin, C. B. J., Rudd, S. G., & Herold, N. (2018) · Cancers · doi:10.3390/cancers10070240 · Cited by 157
“, 5-FU, floxuridine, 5-FU pro-drug capecitabine) [184,185].”
Colorectal Cancer: Disease Process, Current Treatment Options, and Future Perspectives
Adebayo, A. S., Agbaje, K. O., Adesina, S. K., & Olajubutu, O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15112620 · Cited by 157
Balachandran, V., Antony, J., Haritha, N. H., Puliyappadamba, V. T., Saikia, M., Narayanan, S. S., Bevin, A., & Anto, R. J. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.26 · Cited by 142
“fluorouracil (5-FU) is widely used in the treatment of many types of cancers including breast cancer.(4) It inhibits cancer”
BackgroundSiemens, H., Jackstadt, R., Kaller, M., & Hermeking, H. (2013) · Oncotarget · doi:10.18632/oncotarget.1202 · Cited by 135
“5-FU, a pyrimidine analog and anti-metabolite [88] trademarked as Efudex, and the anthracycline antibiotic Doxorubicin [89] are often used for chemotherapy.”
Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling.
Maxwell, P. J., Longley, D. B., Latif, T., Boyer, J. D., Allen, W. L., Lynch, M., McDermott, U., Harkin, D. P., Allegra, C. J., & Johnston, P. G. (2003) · PubMed · Cited by 135
Self-citationAn, Q., Robins, P., Lindahl, T., & Barnes, D. E. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2960 · Cited by 134
“5-Fluorouracil (FU) is widely used in the treatment of a range of cancers, particularly colorectal cancer but also cancers of the breast, head-and-neck, and aerodigestive tract ( 1 ).”
BackgroundDrug resistance to 5-FU linked to reactive oxygen species modulator 1
Hwang, I. T., Chung, Y. M., Kim, J. J., Chung, J. S., Kim, B. S., Kim, H. J., Kim, J. S., & Yoo, Y. D. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.05.088 · Cited by 133
Mattia, E. D., & Toffoli, G. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.12.004 · Cited by 134
Targeting DNA repair pathway in cancer: Mechanisms and clinical application
Wang, M., Chen, S., & Ao, D. (2021) · MedComm · doi:10.1002/mco2.103 · Cited by 150
Azhar, F. F., & Olad, A. (2014) · Applied Clay Science · doi:10.1016/j.clay.2014.09.004 · Cited by 135
PharmGKB summary: fluoropyrimidine pathways
Thorn, C. F., Marsh, S., Whirl‐Carrillo, M., McLeod, H. L., Klein, T. E., & Altman, R. B. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833c6107 · Cited by 142
Extracellular Vesicle-derived circular RNAs confers chemoresistance in Colorectal cancer
Hon, K. W., Mutalib, N. A., Abdullah, N. M. A., Jamal, R., & Abu, N. (2019) · Scientific Reports · doi:10.1038/s41598-019-53063-y · Cited by 142
Tailor‐Made Amino Acids and Fluorinated Motifs as Prominent Traits in Modern Pharmaceuticals
Mei, H., Han, J., White, S., Graham, D. J., Izawa, K., Sato, T., Fustero, S., Meanwell, N. A., & Soloshonok, V. A. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202000617 · Cited by 141
Cancer cell adaptation to chemotherapy
Di Nicolantonio, F., Mercer, S. J., Knight, L. A., Gabriel, F. G., Whitehouse, P. A., Sharma, S., Fernando, A., Glaysher, S., Di Palma, S., Johnson, P., et al. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-78 · Cited by 133
“We then determined the relative mRNA levels of enzymes that have previously been correlated with 5-FU sensitivity: dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP) and thymidylate synthase (TS) [18].”
BackgroundResultDNA polymerase delta in dna replication and genome maintenance
Prindle, M. J., & Loeb, L. A. (2012) · Environmental and Molecular Mutagenesis · doi:10.1002/em.21745 · Cited by 154
“Nucleoside analogs have been in use as antineoplastic agents for decades, and they can often act as mutagens, in addition to their more established role as inhibitors of deoxynucleotide metabolism [Longley et al., 2003; Shao et al., 2006].”
BackgroundPEGylated PLGA nanoparticles: unlocking advanced strategies for cancer therapy
Kesharwani, P., Kumar, V., Goh, K. W., Gupta, G., Alsayari, A., Wahab, S., & Sahebkar, A. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02410-x · Cited by 132
“It primarily functions as an inhibitor of thymidylate synthase and, in turn, causes cancer cells to undergo apoptosis [196].”
Astrocyte elevated gene-1 (AEG-1): A multifunctional regulator of normal and abnormal physiology
Yoo, B. K., Emdad, L., Lee, S., Su, Z.-Z., Santhekadur, P. K., Chen, D., Gredler, R., Fisher, P. B., & Sarkar, D. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.008 · Cited by 134
“5-FU works by inhibiting thymidylate synthase (TS), an enzyme necessary for DNA synthesis, and LSF transcriptionally regulates TS expression (Powell et al., 2000; Longley et al., 2003).”
BackgroundMRP8/ABCC11 directly confers resistance to 5-fluorouracil
Oguri, T., Bessho, Y., Achiwa, H., Ozasa, H., Maeno, K., 前田, 浩., Sato, S., & Ueda, R. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0529 · Cited by 132
The role of pharmacogenetics in capecitabine efficacy and toxicity
Lam, S. W., Guchelaar, H., & Boven, E. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.08.001 · Cited by 132
Lannagan, T. R. M., Lee, Y. K., Wang, T., Roper, J., Bettington, M. L., Fennell, L., Vrbanac, L., Jonavicius, L., Somashekar, R., Gieniec, K., et al. (2019) · Gut · doi:10.1136/gutjnl-2017-315920 · Cited by 129
Highlights on U.S. FDA-approved fluorinated drugs over the past five years (2018–2022)
Ali, S., & Zhou, J. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115476 · Cited by 135
L-arginine metabolism as pivotal interface of mutual host–microbe interactions in the gut
Nüse, B., Holland, T., Rauh, M., Gerlach, R. G., & Mattner, J. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2222961 · Cited by 141
Zamora-Mora, V., Fernández‐Gutiérrez, M., González‐Gómez, Á., Sanz, B., Román, J. S., Goya, G. F., Hernández, R., & Mijangos, C. (2016) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2016.09.084 · Cited by 130
Zhao, Y., Feng, X., Chen, Y., Selfridge, J. E., Gorityala, S., Du, Z., Wang, J. M., Hao, Y., Cioffi, G., Conlon, R. A., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0600 · Cited by 129
“We thus used a cellular thermal shift assay (40) to test if CB-839 treatment enhanced engagement of FdUMP with its target thymidylate synthase (TS), a major mechanism of 5-FU cytotoxicity (41).”
BackgroundMethodGenome‐wide analysis of gene expression in human intrahepatic cholangiocarcinoma†
Obama, K., Ura, K., Li, M., Katagiri, T., Tsunoda, T., Nomura, A., Satoh, S., Nakamura, Y., & Furukawa, Y. (2005) · Hepatology · doi:10.1002/hep.20718 · Cited by 130
RP–MDM2–p53 Pathway: Linking Ribosomal Biogenesis and Tumor Surveillance
Liu, Y., Deisenroth, C., & Zhang, Y. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.03.002 · Cited by 127
“Inhibition of RNA Pol I by a low concentration of actinomycin D (<10 nM) or 5-fluorouracil (5-FU) can induce breakdown of nucleolar structure and activate a p53 stress response [30–32].”
BackgroundHamouda, N., Sano, T., Oikawa, Y., Ozaki, T., Shimakawa, M., Matsumoto, K., Amagase, K., Higuchi, K., & Kato, S. (2017) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12793 · Cited by 133
Host and gut bacteria share metabolic pathways for anti-cancer drug metabolism
Spanogiannopoulos, P., Kyaw, T. S., Guthrie, B. G. H., Bradley, P. H., Lee, J. V., Melamed, J., Malig, Y. N. A., Lam, K. N., Gempis, D., Sandy, M., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01226-5 · Cited by 132
Linking uracil base excision repair and 5-fluorouracil toxicity in yeast
Seiple, L. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj430 · Cited by 126
“This is the major de novo pathway by which the cell produces thymidine precursors for DNA replication, and it is widely accepted that depletion of thymidine nucleotides for DNA synthesis following 5-FU treatment directly results in 5-FU cell killing (‘thymineless death’) (4).”
BackgroundDeciphering cellular states of innate tumor drug responses
Graudens, E., Boulanger, V., Mollard, C., Mariage-Samson, R., Barlet, X., Grémy, G., Couillault, C., Lajémi, M., Piatier-Tonneau, D., Zaborski, P., et al. (2006) · Genome Biology · doi:10.1186/gb-2006-7-3-r19 · Cited by 126
“In CRC, such gene-bygene molecular biology studies have highlighted only a partial list of candidate genes [28-33]; some of these genes were shown to be involved in mechanisms altering drug metabolite potency, others are known to participate in increase of drug efflux or decrease of drug toxicity, or to participate in…”
BackgroundWnt pathway is involved in 5-FU drug resistance of colorectal cancer cells
He, L., Zhu, H., Zhou, S., Wu, T., Wu, H., Yang, H., Mao, H., SekharKathera, C., Janardhan, A., Edick, A. M., et al. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0128-8 · Cited by 125
FOXM1 modulates 5-FU resistance in colorectal cancer through regulating TYMS expression
Varghese, V., Magnani, L., Harada-Shoji, N., Mauri, F., Szydlo, R. M., Yao, S., Lam, E. W.-F., & Kenny, L. M. (2019) · Scientific Reports · doi:10.1038/s41598-018-38017-0 · Cited by 130
5‐Fluorouracil‐based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes
Pardini, B., Kumar, R., Naccarati, A., Novotný, J. P., Prasad, R. B., Försti, A., Hemminki, K., Vodička, P., & Bermejo, J. L. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03892.x · Cited by 143
Pettersen, H. S., Visnes, T., Vågbø, C. B., Svaasand, E. K., Doseth, B., Slupphaug, G., Kavli, B., & Krokan, H. E. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr563 · Cited by 125
“Furthermore, long repair tracts produced during MMR may be cytotoxic and mutagenic in cells having imbalanced nucleotide pools (1,15).”
BackgroundMa, W. W., Saif, M. W., El‐Rayes, B. F., Fakih, M., Cartwright, T. H., Posey, J. A., King, T. R., von Borstel, R. W., & Bamat, M. K. (2016) · Cancer · doi:10.1002/cncr.30321 · Cited by 125
“Longley et al.(33) Used with permission.”
BackgroundInfluentialMarcuello, E., Altés, A., del Río, E., César, A., Menoyo, A., & Baiget, M. (2004) · International Journal of Cancer · doi:10.1002/ijc.20487 · Cited by 125
Dotor, E., Cuatrecases, M., Martínez‐Iniesta, M., Navarro, M., Vilardell, F., Guinó, E., Pareja, L., Figueras, A., Molleví, D. G., Serrano, T., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.5253 · Cited by 142
Autophagy in tumorigenesis and cancer therapy: Dr. Jekyll or Mr. Hyde?
Zhou, S., Zhao, L., Kuang, M., Zhang, B., Liang, Z., Yi, T., Wei, Y., & Zhao, X. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.02.017 · Cited by 136
Yu, X., Shi, W., Zhang, Y., Wang, X., Sun, S., Song, Z., Liu, M., Zeng, Q., Cui, S., & Qu, X. (2017) · Scientific Reports · doi:10.1038/srep42226 · Cited by 125
Jiang, W., Xia, J., Xie, S., Zou, R., Pan, S., Wang, Z. P., Assaraf, Y. G., & Zhu, X. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100683 · Cited by 132
CircRNAs in anticancer drug resistance: recent advances and future potential
Xu, T., Wang, M., Jiang, L., Ma, L., Wan, L., Chen, Q., Wei, C., & Wang, Z. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01240-3 · Cited by 128
JNK2-dependent regulation of SIRT1 protein stability
Ford, J., Ahmed, S., Allison, S., Jiang, M., & Milner, J. (2008) · Cell Cycle · doi:10.4161/cc.7.19.6799 · Cited by 127
Alteration of enzyme specificity by computational loop remodeling and design
Murphy, P. M., Bolduc, J. M., Gallaher, J. L., Stoddard, B. L., & Baker, D. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811070106 · Cited by 126
ABC transporters and their role in nucleoside and nucleotide drug resistance
Fukuda, Y., & Schuetz, J. D. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.12.042 · Cited by 121
“Some purine and pyrimidine-based drugs are phosphorylated by deoxycytidine kinase (dCK), whereby nucleobase drugs such as the thiopurines and 5-fluorouracil (5-FU) can be converted to nucleoside monophosphates by specific phosphoribosyltransferases that add a ribosyl phosphate group [80,81].”
Background5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers
Kraak, L. V. D., Goel, G., Ramanan, K., Kaltenmeier, C., Zhang, L., Normolle, D. P., Freeman, G. J., Tang, D., Nason, K. S., Davison, J. M., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0163-8 · Cited by 125
“It induces cell death through the inhibition of thymidylate synthase and through its misincorporation into newly synthesized DNA and RNA [4].”
BackgroundMetabolic suppression identifies new antibacterial inhibitors under nutrient limitation
Zlitni, S., Ferruccio, L. F., & Brown, E. D. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1361 · Cited by 124
Genomewide Gene Expression Profiles of HPV-Positive and HPV-Negative Oropharyngeal Cancer
Lohavanichbutr, P., Houck, J., Fan, W., Yueh, B., Méndez, E., Futran, N. D., Doody, D. R., Upton, M. P., Farwell, D. G., Schwartz, S. M., et al. (2009) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archoto.2008.540 · Cited by 122
DNA Mismatch Repair-dependent Response to Fluoropyrimidine-generated Damage
Meyers, M., Wagner, M. W., Mazurek, A., Schmütte, C., Fishel, R. A., & Boothman, D. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m412105200 · Cited by 126
Fluoxetine improves the memory deficits caused by the chemotherapy agent 5-fluorouracil
ELBeltagy, M., Mustafa, S., Umka, J., Lyons, L., Salman, A., Tu, C.-Y. G., Bhalla, N., Bennett, G. W., & Wigmore, P. M. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.11.017 · Cited by 142
5-Fluorouracil derivatives: a patent review
Alvarez, P. J., Marchal, J. A., Boulaiz, H., Carrillo, E., Vélez, C., Rodríguez‐Serrano, F., Melguizo, C., Prados, J. C., Madeddu, R., & Aránega, A. (2012) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2012.661413 · Cited by 145
“Approximately 90% of an administered dose of 5-FU is catabolized by DPD in the liver, peripheral blood mononuclear cells, intestinal mucosa, pancreas, lungs and kidneys; only 10% is excreted unchanged in the urine (Figure 2) [25-28].”
BackgroundInfluential
Metadata
- Authors
- Longley, D. B., Harkin, D. P., & Johnston, P. G.
- Affiliations
- Queen's University Belfast (GB)
- Corresponding author
- Johnston, Patrick G.
- ORCID
- Longley, Daniel B.
- Venue
- Nature Reviews Cancer
- Published
- 2003-05
- Volume
- 3
- Issue
- 5
- Pages
- 330-338
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1984328540
- Cited by
- 5,332
- References
- 111
- Citations by year
- 2026: 293 · 2025: 350 · 2024: 391 · 2023: 377 · 2022: 435 · 2021: 398 · 2020: 408 · 2019: 324 · 2018: 299 · 2017: 289 · 2016: 257 · 2015: 251 · 2014: 221 · 2013: 193 · 2012: 154
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- 5-fluorouracil, mechanism of action, drug resistance, predictive biomarkers, chemotherapeutic target, anticancer activity, cancer chemotherapy
- MeSH terms
- Animals, Antimetabolites, Antineoplastic, Fluorouracil, Humans, Interferons, Oxidoreductases, RNA, Thymidine Phosphorylase, Thymidylate Synthase, Biomarkers, Tumor Suppressor Protein p53, Microsatellite Repeats, Oligonucleotide Array Sequence Analysis, Dihydrouracil Dehydrogenase (NADP)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.